{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:08:17Z","timestamp":1792087697361,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.psychres.2019.06.020","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T08:18:13Z","timestamp":1561105093000},"page":"294-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis"],"prefix":"10.1016","volume":"278","author":[{"given":"J.N.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vingerhoets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hirdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.M.","family":"McAlonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.V.","family":"Amelsvoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Zinkstok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2019.06.020_bib0001","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/S0924-977X(15)30061-4","article-title":"Pharmacological modulation of excitatory\/ inhibitory balance in autism spectrum disorder","volume":"25","author":"Ajram","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2019.06.020_bib0002","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0924-977X(15)30061-4","article-title":"Pharmacological modulation of excitatory\/inhibitory balance in autism spectrum disorder","volume":"25","author":"Ajram","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2019.06.020_bib0003","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","author":"Association","year":"2013"},{"issue":"8","key":"10.1016\/j.psychres.2019.06.020_bib0004","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0028-3908(85)90196-0","article-title":"2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission\u2014II: biochemical properties","volume":"24","author":"Benavides","year":"1985","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2019.06.020_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0924-977X(03)00100-7","article-title":"Glutamate and anxiety","volume":"14","author":"Bergink","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2019.06.020_bib0006","volume":"104","author":"Borenstein","year":"2005"},{"key":"10.1016\/j.psychres.2019.06.020_bib0007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1360-0443.2005.00985.x","article-title":"Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence","volume":"100","author":"Ciraulo","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.psychres.2019.06.020_bib0008","unstructured":"Cohen, J., 1988. Statistical power analysis for the behavioral sciences. Hilsdale. NJLawrence Earlbaum Assoc. 2."},{"key":"10.1016\/j.psychres.2019.06.020_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2018-320211","article-title":"Evidence for a multimodal effect of riluzole in patients with ALS?","author":"de Jongh","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0010","doi-asserted-by":"crossref","first-page":"233S","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.psychres.2019.06.020_bib0011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/B:CEMN.0000012717.37839.07","article-title":"Riluzole enhances glutamate uptake in rat astrocyte cultures","volume":"24","author":"dos Santos Frizzo","year":"2004","journal-title":"Cell. Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.psychres.2019.06.020_bib0012","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1037\/1082-989X.1.2.170","article-title":"Meta-analysis of experiments with matched groups or repeated measures designs","volume":"1","author":"Dunlap","year":"1996","journal-title":"Psychological methods"},{"issue":"8","key":"10.1016\/j.psychres.2019.06.020_bib0013","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/pcn.12394","article-title":"Riluzole in augmentation of fluvoxamine for moderate to severe obsessive\u2013compulsive disorder: randomized, double-blind, placebo-controlled study","volume":"70","author":"Emamzadehfard","year":"2016","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.psychres.2019.06.020_bib0014","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269881118817166","article-title":"Riluzole for treatment of men with methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial","volume":"33","author":"Farahzadi","year":"2018","journal-title":"J. Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psychres.2019.06.020_bib0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00213-013-3261-z","article-title":"A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia","volume":"231","author":"Farokhnia","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2019.06.020_bib0016","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV","author":"Frances","year":"1994"},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0017","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40272-013-0036-2","article-title":"Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial","volume":"15","author":"Ghaleiha","year":"2013","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.psychres.2019.06.020_bib0018","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1155\/2013\/536521","article-title":"Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism","volume":"35","author":"Ghanizadeh","year":"2013","journal-title":"Dis. Markers"},{"key":"10.1016\/j.psychres.2019.06.020_bib0019","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The yale-brown obsessive compulsive scale: II. Validity","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0020","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2019.06.020_bib0021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/cap.2010.0009","article-title":"Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder","volume":"20","author":"Grant","year":"2010","journal-title":"Journal of child and adolescent psychopharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0022","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/npp.2013.343","article-title":"12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder","volume":"39","author":"Grant","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2019.06.020_bib0023","series-title":"Assessment of Depression","first-page":"143","article-title":"The Hamilton rating scale for depression","author":"Hamilton","year":"1986"},{"issue":"2","key":"10.1016\/j.psychres.2019.06.020_bib0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0028-3908(01)00175-7","article-title":"Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function","volume":"42","author":"He","year":"2002","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0025","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1037\/0022-3514.84.6.1140","article-title":"Transfer of value from fit","volume":"84","author":"Higgins","year":"2003","journal-title":"J. Pers. Soc. Psychol."},{"key":"10.1016\/j.psychres.2019.06.020_bib0026","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.psychres.2019.06.020_bib0027","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","article-title":"The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies","volume":"1338","author":"Hu","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0028","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs Add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2019.06.020_bib0029","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00210-008-0290-y","article-title":"Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABAA-receptors","volume":"378","author":"Jahn","year":"2008","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0030","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/sj.bjp.0703424","article-title":"Effects of riluzole on electrically evoked neurotransmitter release","volume":"130","author":"Jehle","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.psychres.2019.06.020_bib0031","first-page":"S228","article-title":"A placebo-controlled trial of riluzole for treatment of childhood-onset obsessive compulsive disorder","volume":"36","author":"Joseph","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0032","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pediatrneurol.2015.02.002","article-title":"Efficacy of glutamate modulators in tic suppression: a double-blind, randomized control trial of D-serine and riluzole in tourette syndrome","volume":"52","author":"Lemmon","year":"2015","journal-title":"Pediatr. Neurol"},{"key":"10.1016\/j.psychres.2019.06.020_bib0033","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/009127009903900507","article-title":"A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers","volume":"39","author":"Liboux","year":"1999","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2019.06.020_bib0034","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2015.06.034","article-title":"FOXG1-dependent dysregulation of GABA\/glutamate neuron differentiation in autism spectrum disorders","volume":"162","author":"Mariani","year":"2015","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.psychres.2019.06.020_bib0035","first-page":"S161","article-title":"A randomized, placebo-controlled adjunctive trial of riluzole in treatment-resistant major depressive disorder","volume":"40","author":"Mathew","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.psychres.2019.06.020_bib0036","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/npp.2017.106","article-title":"A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive riluzole for treatment-resistant major depressive disorder","volume":"42","author":"Mathew","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2019.06.020_bib0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0038","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1092852900016734","article-title":"Inflammation, glutamate, and glia in depression: a literature review","volume":"13","author":"McNally","year":"2008","journal-title":"CNS Spectr"},{"issue":"3","key":"10.1016\/j.psychres.2019.06.020_bib0039","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst. Rev"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2019.06.020_bib0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(01)00847-0","article-title":"Interaction of the neuroprotective drug riluzole with GABAA and glycine receptor channels","volume":"415","author":"Mohammadi","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2019.06.020_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev"},{"issue":"4","key":"10.1016\/j.psychres.2019.06.020_bib0042","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2019.06.020_bib0043","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.mp.4002006","article-title":"The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression","volume":"12","author":"M\u00fcller","year":"2007","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2019.06.020_bib0044","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.biopsych.2016.07.005","article-title":"Ketamine for depression: an update","volume":"80","author":"Murrough","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0045","unstructured":"National Collaborating Centre for Woman's and Children's Health (2011) Autism: Recognition, Referral and Diagnosis of Children and Young People on the Autism Spectrum (NICE Clinical Guidelines, No. 170)., 2013."},{"key":"10.1016\/j.psychres.2019.06.020_bib0046","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpsychires.2014.07.022","article-title":"Riluzole likely lacks antidepressant efficacy in ketamine non-responders","volume":"58","author":"Niciu","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2019.06.020_bib0047","unstructured":"Nicolson, R., Bennett, T., Akintan, O., Harvey, C., Brian, J., Capano, L., Hodgins, C., Kraus de Camargo, O., Mankad, D., Ahmad, A., Chalupka, M., Colli, L., Genore, L., Greco, A., Lui, T., Iaboni, A., O'Connor, I., Odrobina, D., Thorpe, K., Anagnostou, E., 2017. A randomized controlled trial of riluzole in autism spectrum disorder, in: INSAR. Retrieved from: https:\/\/insar.confex.com\/insar\/2017\/webprogram\/Paper25321.html."},{"issue":"3","key":"10.1016\/j.psychres.2019.06.020_bib0048","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0000000000000693","article-title":"A double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression","volume":"37","author":"Park","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2019.06.020_bib0049","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/09297040500253546","article-title":"Neurobiological correlates of autism: a review of recent research","volume":"12","author":"Penn","year":"2006","journal-title":"Child Neuropsychol"},{"key":"10.1016\/j.psychres.2019.06.020_bib0050","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-019-5188-5","article-title":"Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications","author":"Pillinger","year":"2019","journal-title":"Psychopharmacology"},{"issue":"08","key":"10.1016\/j.psychres.2019.06.020_bib0051","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0052","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00023210-200822090-00004","article-title":"Riluzole in the treatment of mood and anxiety disorders","volume":"22","author":"Pittenger","year":"2008","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.psychres.2019.06.020_bib0053","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0054","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/1547691X.2010.538749","article-title":"Theoretical aspects of autism: biomarkers\u2014a review","volume":"8","author":"Ratajczak","year":"2011","journal-title":"J. Immunotoxicol."},{"issue":"2","key":"10.1016\/j.psychres.2019.06.020_bib0055","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0056","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpsychires.2016.01.003","article-title":"Riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"75","author":"Salardini","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2019.06.020_bib0057","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children's Yale\u2013Brown obsessive compulsive scale: reliability and validity","volume":"36","author":"Scahill","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0058","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/eb-2016-102355","article-title":"Ketamine for treatment-resistant depression: recent developments and clinical applications","volume":"19","author":"Schwartz","year":"2016","journal-title":"Evid. Based. Ment. Health"},{"issue":"2","key":"10.1016\/j.psychres.2019.06.020_bib0059","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd1630","article-title":"Metabotropic glutamate receptors as novel targets for anxiety and stress disorders","volume":"4","author":"Swanson","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.psychres.2019.06.020_bib0060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin. Neurosci"},{"issue":"10","key":"10.1016\/j.psychres.2019.06.020_bib0061","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1046\/j.1460-9568.2000.00242.x","article-title":"Riluzole inhibits the persistent sodium current in mammalian CNS neurons","volume":"12","author":"Urbani","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.psychres.2019.06.020_bib0062","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1093\/schbul\/sby016.449","article-title":"GABA and glutamate in patients with 22q11.2 deletion syndrome and healthy volunteers and the relation with cognition: a randomized doubleblind 7Tesla pharmacological mrs study","volume":"44","author":"Vingerhoets","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2019.06.020_bib0063","first-page":"514","article-title":"Serum and plasma brain-derived neurotrophic factor and response in a multi-site, randomized controlled trial of riluzole for treatment resistant depression","volume":"79","author":"Wilkinson","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2019.06.020_bib0064","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jad.2018.08.075","article-title":"Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression","volume":"241","author":"Wilkinson","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.psychres.2019.06.020_bib0065","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1007\/s10803-018-3562-5","article-title":"A randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder","volume":"48","author":"Wink","year":"2018","journal-title":"J. Autism Dev. Disord. J. Autism Childhood Schizophr."},{"key":"10.1016\/j.psychres.2019.06.020_bib0066","first-page":"S44","article-title":"Is synaptic plasticity involved in the mechanism underlying the rapid antidepressant effects of N-Methyl-D-aspartate receptor antagonists?","volume":"36","author":"Zarate","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2019.06.020_bib0067","doi-asserted-by":"crossref","unstructured":"Zarate, C.A. Jr., Manji, H.K., 2008. Riluzole in psychiatry: a systematic review of the literature. Expert Opin. Drug Metab. Toxicol.4, 1223\u20131234.","DOI":"10.1517\/17425255.4.9.1223"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119310844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119310844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:37:51Z","timestamp":1759037871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178119310844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":67,"alternative-id":["S0165178119310844"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2019.06.020","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2019.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}